Evotec, Novo Nordisk Form Research Alliance In Diabetes And Obesity

Shutterstock photo

(RTTNews.com) - Evotec AG (EVTCY.PK, EVOTF.PK) announced a strategic alliance with Novo Nordisk (NVO) to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co-morbidities such as nonalcoholic steatohepatitis or "NASH", cardiovascular diseases, and diabetic kidney disease. No financial details of the alliance were disclosed.

Evotec said it will apply its drug discovery platform, especially in ligand-based design, to seek to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitable pre-clinical candidates are selected, Novo Nordisk will use Evotec's INDiGO platform to move through pre-clinical studies to enter IND registration.

Read the original article on RTTNews (http://www.rttnews.com/2928551/evotec-novo-nordisk-form-research-alliance-in-diabetes-and-obesity.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Economy
Referenced Symbols: EVTCY ,

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?